Are we overlooking stage a prostate cancer in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities?

Jeffrey N. Kocurek, Eduardo Orihuela, Durwood E. Neal, Mariela Pow-Sang, Michael M. Warren

Research output: Contribution to journalArticle

Abstract

Our objective was to assess the likelihood of overlooking the diagnosis of prostate cancer (PCA), using current screening methods, in patients treated for benign prostatic hyperplasia (BPH) with medical or minimally invasive treatment modalities, which do not produce tissue specimens for histologic review. To appraise this, we examined the impact of the preoperative use of prostatic specific antigen (PSA) in combination with transrectal ultrasound (TRUS) and systematic sextant prostate needle biopsy (PNbx) on the subsequent incidence of stage A PCA in patients undergoing transurethral resection of the prostate (TURP). After excluding all patients found to have PCA during pretreatment screening, 485 patients who underwent TURP for presumed BPH from 1976 to 1994 were reviewed. From 1976 to 1989, PSA was not used for pretreatment screening, and stage A PCA was diagnosed in 11.4% of 317 patients. In 1990 and 1991, pretreatment screening included PNbx obtained under ultrasound guidance for PSA of 15.0 ng/ml or greater. Stage A PCA was diagnosed in 14.2% of 63 patients. From 1992 to 1994, pretreatment screening included systematic sextant PNbx performed for PSA greater than 4.0 ng/ml, and stage A PCA was diagnosed in 2.8% of 105 patients. The difference in incidence of stage A PCA between the first two groups and group three was significant (p = 0.021), as it was the difference in incidence of stage A2 (P = 0.037). For stage A1, the difference did not reach statistical significance (p = 0.089). Our findings suggest that systematic sextant PNbx for PSA greater than 4.0 ng/ml significantly reduces the risk of overlooking prostate cancer in patients undergoing treatment of BPH with modalities that do not provide tissue specimens.

Original languageEnglish (US)
Pages (from-to)153-155
Number of pages3
JournalUrologic Oncology: Seminars and Original Investigations
Volume1
Issue number4
DOIs
StatePublished - 1995

Fingerprint

Prostatic Hyperplasia
Prostatic Neoplasms
Antigens
Transurethral Resection of Prostate
Incidence
Needle Biopsy
varespladib methyl
Prostate
Therapeutics

Keywords

  • benign prostatic hyperplasia
  • Prostate cancer
  • prostatectomy
  • prostatic specific antigen screening

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Are we overlooking stage a prostate cancer in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities? / Kocurek, Jeffrey N.; Orihuela, Eduardo; Neal, Durwood E.; Pow-Sang, Mariela; Warren, Michael M.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 1, No. 4, 1995, p. 153-155.

Research output: Contribution to journalArticle

Kocurek, Jeffrey N. ; Orihuela, Eduardo ; Neal, Durwood E. ; Pow-Sang, Mariela ; Warren, Michael M. / Are we overlooking stage a prostate cancer in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities?. In: Urologic Oncology: Seminars and Original Investigations. 1995 ; Vol. 1, No. 4. pp. 153-155.
@article{85f07efeb7fb4e28981c0a443f2571e5,
title = "Are we overlooking stage a prostate cancer in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities?",
abstract = "Our objective was to assess the likelihood of overlooking the diagnosis of prostate cancer (PCA), using current screening methods, in patients treated for benign prostatic hyperplasia (BPH) with medical or minimally invasive treatment modalities, which do not produce tissue specimens for histologic review. To appraise this, we examined the impact of the preoperative use of prostatic specific antigen (PSA) in combination with transrectal ultrasound (TRUS) and systematic sextant prostate needle biopsy (PNbx) on the subsequent incidence of stage A PCA in patients undergoing transurethral resection of the prostate (TURP). After excluding all patients found to have PCA during pretreatment screening, 485 patients who underwent TURP for presumed BPH from 1976 to 1994 were reviewed. From 1976 to 1989, PSA was not used for pretreatment screening, and stage A PCA was diagnosed in 11.4{\%} of 317 patients. In 1990 and 1991, pretreatment screening included PNbx obtained under ultrasound guidance for PSA of 15.0 ng/ml or greater. Stage A PCA was diagnosed in 14.2{\%} of 63 patients. From 1992 to 1994, pretreatment screening included systematic sextant PNbx performed for PSA greater than 4.0 ng/ml, and stage A PCA was diagnosed in 2.8{\%} of 105 patients. The difference in incidence of stage A PCA between the first two groups and group three was significant (p = 0.021), as it was the difference in incidence of stage A2 (P = 0.037). For stage A1, the difference did not reach statistical significance (p = 0.089). Our findings suggest that systematic sextant PNbx for PSA greater than 4.0 ng/ml significantly reduces the risk of overlooking prostate cancer in patients undergoing treatment of BPH with modalities that do not provide tissue specimens.",
keywords = "benign prostatic hyperplasia, Prostate cancer, prostatectomy, prostatic specific antigen screening",
author = "Kocurek, {Jeffrey N.} and Eduardo Orihuela and Neal, {Durwood E.} and Mariela Pow-Sang and Warren, {Michael M.}",
year = "1995",
doi = "10.1016/1078-1439(95)00060-7",
language = "English (US)",
volume = "1",
pages = "153--155",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Are we overlooking stage a prostate cancer in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities?

AU - Kocurek, Jeffrey N.

AU - Orihuela, Eduardo

AU - Neal, Durwood E.

AU - Pow-Sang, Mariela

AU - Warren, Michael M.

PY - 1995

Y1 - 1995

N2 - Our objective was to assess the likelihood of overlooking the diagnosis of prostate cancer (PCA), using current screening methods, in patients treated for benign prostatic hyperplasia (BPH) with medical or minimally invasive treatment modalities, which do not produce tissue specimens for histologic review. To appraise this, we examined the impact of the preoperative use of prostatic specific antigen (PSA) in combination with transrectal ultrasound (TRUS) and systematic sextant prostate needle biopsy (PNbx) on the subsequent incidence of stage A PCA in patients undergoing transurethral resection of the prostate (TURP). After excluding all patients found to have PCA during pretreatment screening, 485 patients who underwent TURP for presumed BPH from 1976 to 1994 were reviewed. From 1976 to 1989, PSA was not used for pretreatment screening, and stage A PCA was diagnosed in 11.4% of 317 patients. In 1990 and 1991, pretreatment screening included PNbx obtained under ultrasound guidance for PSA of 15.0 ng/ml or greater. Stage A PCA was diagnosed in 14.2% of 63 patients. From 1992 to 1994, pretreatment screening included systematic sextant PNbx performed for PSA greater than 4.0 ng/ml, and stage A PCA was diagnosed in 2.8% of 105 patients. The difference in incidence of stage A PCA between the first two groups and group three was significant (p = 0.021), as it was the difference in incidence of stage A2 (P = 0.037). For stage A1, the difference did not reach statistical significance (p = 0.089). Our findings suggest that systematic sextant PNbx for PSA greater than 4.0 ng/ml significantly reduces the risk of overlooking prostate cancer in patients undergoing treatment of BPH with modalities that do not provide tissue specimens.

AB - Our objective was to assess the likelihood of overlooking the diagnosis of prostate cancer (PCA), using current screening methods, in patients treated for benign prostatic hyperplasia (BPH) with medical or minimally invasive treatment modalities, which do not produce tissue specimens for histologic review. To appraise this, we examined the impact of the preoperative use of prostatic specific antigen (PSA) in combination with transrectal ultrasound (TRUS) and systematic sextant prostate needle biopsy (PNbx) on the subsequent incidence of stage A PCA in patients undergoing transurethral resection of the prostate (TURP). After excluding all patients found to have PCA during pretreatment screening, 485 patients who underwent TURP for presumed BPH from 1976 to 1994 were reviewed. From 1976 to 1989, PSA was not used for pretreatment screening, and stage A PCA was diagnosed in 11.4% of 317 patients. In 1990 and 1991, pretreatment screening included PNbx obtained under ultrasound guidance for PSA of 15.0 ng/ml or greater. Stage A PCA was diagnosed in 14.2% of 63 patients. From 1992 to 1994, pretreatment screening included systematic sextant PNbx performed for PSA greater than 4.0 ng/ml, and stage A PCA was diagnosed in 2.8% of 105 patients. The difference in incidence of stage A PCA between the first two groups and group three was significant (p = 0.021), as it was the difference in incidence of stage A2 (P = 0.037). For stage A1, the difference did not reach statistical significance (p = 0.089). Our findings suggest that systematic sextant PNbx for PSA greater than 4.0 ng/ml significantly reduces the risk of overlooking prostate cancer in patients undergoing treatment of BPH with modalities that do not provide tissue specimens.

KW - benign prostatic hyperplasia

KW - Prostate cancer

KW - prostatectomy

KW - prostatic specific antigen screening

UR - http://www.scopus.com/inward/record.url?scp=58149365444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149365444&partnerID=8YFLogxK

U2 - 10.1016/1078-1439(95)00060-7

DO - 10.1016/1078-1439(95)00060-7

M3 - Article

AN - SCOPUS:58149365444

VL - 1

SP - 153

EP - 155

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 4

ER -